REXNESSVY
Glaxo Group Limited
| Research |
OneLook
Acronym Finder
|
| Serial Number | 97542610 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Elizabeth K. Rucki |
| Attorney Docket Number | 84187212 |
Timeline
| 2022-08-10 | Application Filed |
| 2022-08-13 | Location: NEW APPLICATION PROCESSING |
| 2022-08-13 | Status: Live/Pending |
| 2022-08-13 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Glaxo Group Limited |
| Entity Statement | private company limited by shares (prc) |
| Address | 980 Great West Road Brentford, Middles GB TW89GS GB2 |
| Legal Entity Type | |
| Legal Entity State | GB |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | (Based on Intent to Use) Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders(Based on 44(d) Priority Application) Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders |
| GS0051 | Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2022-08-13 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2022-08-30 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2023-05-26 | 3 DOCK D:Assigned to Examiner |
| SUSPENSION LETTER WRITTEN | 2023-05-30 | 4 CNSL R:Renewal |
| LETTER OF SUSPENSION E-MAILED | 2023-05-30 | 5 GNSL F:First Action |
| NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | 2023-05-30 | 6 GNS3 O:Outgoing Correspondence |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2023-07-12 | 7 COAR I:Incoming Correspondence |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2023-07-12 | 8 CHAN I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2023-07-12 | 9 TCCA I:Incoming Correspondence |
| TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | 2023-09-27 | 10 ERSI I:Incoming Correspondence |
| SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | 2024-01-10 | 11 RCCK S: |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2024-03-15 | 12 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2024-03-15 | 13 TEME I:Incoming Correspondence |
| SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | 2024-03-18 | 14 RCCK S: |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2024-03-18 | 15 CNSA O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2024-04-03 | 16 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2024-04-23 | 17 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2024-04-23 | 18 NPUB E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2024-07-09 | 19 R.PR A:Allowance for Publication |
| NOTICE OF REGISTRATION CONFIRMATION EMAILED | 2024-07-09 | 20 NRCC E:E-Mail |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 